Subscribe to our newsletter.
IDH 1/2 mutations pertains to alterations in the genes IDH1 and IDH2, often seen in conditions like acute myeloid leukemia and brain tumors such as gliomas. These genetic changes result in abnormal cellular metabolism that supports cancer growth. Testing for IDH 1/2 mutations is vital for diagnosis, prognosis, and choosing the appropriate treatment plan. Drugs that specifically target these mutated enzymes are available, making it crucial to identify these mutations for personalized treatment approaches. Thus, evaluating for IDH 1/2 mutations has become a cornerstone in the comprehensive care of specific cancer types.